Bicycle Therapeutics - BCYC Stock Forecast, Price & News

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC opened at $26.40 on Tuesday. The company has a quick ratio of 9.88, a current ratio of 9.88 and a debt-to-equity ratio of 0.10. Bicycle Therapeutics has a fifty-two week low of $12.08 and a fifty-two week high of $62.08. The stock's 50-day moving average is $19.80 and its two-hundred day moving average is $29.01.

Bicycle Therapeutics (NASDAQ:BCYC - Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Bicycle Therapeutics had a negative net margin of 533.03% and a negative return on equity of 30.07%. Sell-side analysts anticipate that Bicycle Therapeutics will post -3.73 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BCYC shares. TheStreet cut shares of Bicycle Therapeutics from a "c-" rating to a "d+" rating in a research note on Thursday, April 21st. Canaccord Genuity Group reaffirmed a "buy" rating and set a $60.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, July 6th. Piper Sandler lowered their target price on Bicycle Therapeutics from $76.00 to $37.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd. JMP Securities reaffirmed a "buy" rating and set a $70.00 target price on shares of Bicycle Therapeutics in a report on Monday, June 6th. Finally, Barclays assumed coverage on Bicycle Therapeutics in a report on Thursday, July 28th. They set an "overweight" rating and a $30.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.92.